Join
Live feed
·
PRReleasevia Quantisnow
Nanobiotix S.A. logo

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

ByQuantisnow·Wall Street's wire, on your screen.
NBTX· Nanobiotix S.A.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NBTX (Nanobiotix S.A.) and more on Quantisnow.